SUS delivered a strong Q2, beating expectations on both sales and EBIT.
Surgical Science delivered a strong Q2, with sales 6% above our expectations and an EBIT margin of 13% versus our 9% estimate.
Surgical Science demonstrated a solid Q1 which prompted a reasonable share price reaction.
The report was below our estimates on sales, but we found ourselves above analyst consensus, which Q1 sales figures met on sales and surpass...
Surgical Science delivered a decent but slightly soft Q4, facing near-term headwinds from the Intuitive reset while trading at deeply undema...
Redeye provides its initial take on Surgical Science, with sales relatively in line with expectations, though marginally lower profit margin...
Redeye updates its estimates and valuation after Surgical Science’s capital markets day.
Top Picks comments on a significant development that fundamentally changes one of our investment theses.
Redeye comments on Surgical Science dropping an absolute bomb of a press release.
Redeye updates its estimates following Surgical Science’s Q3 2025 report, which featured decent sales but subpar profitability and cash flow...
Redeye provides its initial take on Surgical Science’s Q3 2025 report, which came in slightly below our top-line projection and missed our p...
Redeye updates its estimates following Surgical Science’s Q2 2025 report, which aligned with the company’s profit warning and broadly underp...
Redeye provides its initial take on Surgical Science’s Q2 2025 report, which aligned with its profit warning and underperformed our original...
Redeye negatively views Surgical Science’s profit warning for Q2 2025.
Redeye updates its estimates following Surgical Science’s Q1 2025 report, which beat our projections thanks to segment Educational Products.
Redeye provides its initial take on Surgical Science’s Q1 2025 report, which mostly beat our estimates.
Redeye updates its estimates following Surgical Science’s Q4 2024 report.
Redeye provides its initial take on Surgical Science’s Q4 2024 report, which featured decent top line figures.
Redeye comments on Surgical Science announcing an opportunistic bolt-on deal by offering to acquire all shares in UK-listed Intelligent Ultr...
Redeye updates its estimates following Surgical Science’s Q3 2024 report, which beat our expectations.
Redeye provides its initial take on Surgical Science’s Q3 2024 report, which beat our expectations.
Redeye updates its estimates following Surgical Science’s Q2 2024 report, which featured a sequential recovery after the company’s weak Q1.
Redeye provides its initial take on Surgical Science’s Q2 2024 report, which featured a notable sequential recovery after the company’s weak...
Redeye updates its estimates following Surgical Science’s Q1 2024 report, which came in considerably below our estimates due to weak Educati...
Redeye provides its initial take on Surgical Science’s Q1 2024 report, which featured contrasting developments for the company’s two busines...
Redeye updates its estimates following Surgical Science’s Q4 2023 report, which featured an unusually soft end to the year that we failed to...
Redeye provides its initial take on Surgical Science’s Q4 2023 report, which broadly underperformed our expectations.
Redeye updates its estimates following Surgical Science’s Q3 2023 report, which featured considerably lower-than-expected sales.
Redeye provides its initial take on Surgical Science’s Q3 2023 report, which came in broadly below our estimates.
Redeye updates its estimates following Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’.
Redeye provides its initial take on Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’.
Redeye updates its estimates following Surgical Science’s Q1 2023 report, which took our forecasts to the woodshed.
Redeye provides its initial take on Surgical Science’s Q1 2023 report, which exceeded our estimates in most regards.
Redeye updates its estimates following Surgical Science’s Q4 2022 report, which broadly aligned with our expectations.
Redeye provides its initial take on Surgical Science’s Q4 2022 report, broadly aligning with our estimates.
Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured solid sales growth and profitability.
Redeye provides its initial take on Surgical Science’s Q3 2022 report, which came in above our estimates.
Redeye provides an updated view of our investment thesis of Surgical Science following the company posting excellent Q2 numbers.
Redeye provides its initial take on Surgical Science’s Q2 2022 report, which came in above our estimates.
Redeye initiates coverage of Surgical Science, a serial acquirer sporting healthy organic growth prospects.
